Anokion’s autoimmunity platform evolution

Why Anokion shifted its focus to a platform that delivers tolerance-inducing antigens directly to the liver

When the science suggested the liver, and not the blood, could be the better target tissue for tolerance-inducing autoantigens, Anokion devised a platform around the former. About 18 months after its pivot, the company is poised to bring its first therapy into the clinic before the end of the year, with another one to follow within 12 months.

In the last week, Anokion S.A. closed a $40 million series B round and presented

Read the full 737 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE